1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Erythropoietin Stimulating Agents: Therapeutic Applications and Global Markets

This BCC Research report provides an up-to-date analysis of recent developments and current trends in the global erythropoietin drug market. Includes forecast through 2020.

Use this report to:

Gain information about the various types applications of erythropoietin stimulating agents.
Analyze current trends within the industry, major industry challenges, and the regional dynamics of the global erythropoietin drug market.
Quantify the projected impact of both internal and external forces affecting the global erythropoietin drug market today and over the next several years.
Analyze detailed profiles of major vendors in the erythropoietin drug industry globally.

Highlights

The global market for erythropoietin stimulating agents (ESAs) will grow from nearly $7.2 billion in 2015 to nearly $7.3 billion by 2020 with a compound annual growth rate (CAGR) of 0.2% for the period 2015-2020.
The Epoetin-alfa drug market is the largest segment and should reach approximately $3.3 billion in 2015 and nearly $2.1 billion by 2020, a CAGR of -8.4%.
The Epoetin-omega drug market is expected to increase from nearly $371.8 million in 2015 to nearly $1.1 billion in 2020, a CAGR of 23.3%.

INTRODUCTION

The global market for erythropoietin drug can be broadly classified into two segments:
biologics and biosimilars.
The major types of biologic erythropoietin drugs based on different biological properties are epoetin-alfa, epoetin-beta, darbepoetin-alfa and epoetin-theta.
The major types of biosimilar erythropoietin drug based on the different biological properties are epoetin-zeta, epoetin-omega, epoetin-lambda and epoetin-delta.
The global erythropoietin biologics drug market has been growing in terms of value from the past 15 years in pace with the increasing prevalence of chronic kidney diseases throughout the world, however the market is expected to see decline in the forecast period due to expiry of major patented drugs in the U.S. and European markets; and due to the entrant of many biosimilar erythropoietin drug in the European market since 2008 which are approximately 20% to 30% cheaper compared to patented drug.

The global erythropoietin biosimilars drug market has been growing rapidly in the last decade years, primarily due to the patent expiry of major erythropoietin biologic drug in European market and demand for cheaper priced erythropoietin drugs in the Asia-Pacific, South America, Middle-east and African market. The study covered in this
report has been conducted to analyze and quantify the emerging market opportunities for erythropoietin drug, as well as to highlight the key current research efforts that are driving erythropoietin drug into new applications. In addition, major players of the erythropoietin drug, along with their upcoming and anticipated erythropoietin-related
products are analyzed to demonstrate how these advances might impact global erythropoietin drug market.

The application of erythropoietin drug is divided broadly into three types: chronic kidney diseases; oncology diseases; and other applications such as treatment of anemia in HIV patients. The key drivers for the erythropoietin drug market are increasing case of chronic disease and increasing prevalence of cancer.
Amgen Inc., Hoffmann-La Roche and Johnson & Johnson are some of the key players of biologics erythropoietin drug market. Sandoz (subsidiary of Novartis International AG), Hospira (subsidiary of Pfizer Inc.), 3SBio, BioSidus and Teva Pharmaceutical Industries Ltd. are some of the major players of biosimilar erythropoietin drugs market.
The market for erythropoietin in Asia-Pacific and South America is expected to grow at the fastest rate compared to other global markets, which are expected to decline. The entrant of erythropoietin biosimilars drugs in Europe and the U.S. will create a huge impact during the forecast period, resulting in a decline in the global erythropoietin drug market.

Table Of Contents

Erythropoietin Stimulating Agents: Therapeutic Applications and Global Markets
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 3
REASONS FOR DOING THE STUDY 3
SCOPE OF REPORT 3
INTENDED AUDIENCE 3
INFORMATION SOURCES 4
RESEARCH METHODOLOGY 4
ANALYSTS' CREDENTIALS 4
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 5
DISCLAIMER 5
CHAPTER 2 SUMMARY 7
SUMMARY TABLE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE,
THROUGH 2020 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE,
2014-2020 ($ MILLIONS) 8
CHAPTER 3 OVERVIEW 11
DEFINITION 11
ERYTHROPOIETIN AS A DRUG 12
DEVELOPMENTAL STAGES OF ERYTHROPOIETIN 12
APPLICATIONS OF ERYTHROPOIETIN 13
SIDE EFFECTS OF ERYTHROPOIETIN 14
CARDIOVASCULAR 15
HEMATOLOGIC 15
CENTRAL NERVOUS SYSTEM 15
PSYCHIATRIC 16
ONCOLOGIC 16
GASTROINTESTINAL 16
DERMATOLOGIC 16
PROS AND CONS OF MANUFACTURING METHODS: 16
PROS 16
CONS 16
CHAPTER 4 RandD DRUG PIPELINE 19
TABLE 1 MAJOR EPO R andD DRUG PIPELINE BY TRIAL PHASE 19
CHAPTER 5 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUG 21
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY CATEGORY 21
TABLE 2 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY CATEGORY, THROUGH
2020 ($ MILLIONS) 21
FIGURE 1 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY CATEGORY,
2015 AND 2020 (%) 21
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY TYPE 22
TABLE 3 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020
($ MILLIONS) 23
FIGURE 2 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY TYPE, 2015
AND 2020 (%) 23
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE 25
TABLE 4 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE,
THROUGH 2020 ($ MILLIONS) 25
FIGURE 3 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY
TYPE, 2015 AND 2020 (%) 25
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE 27
TABLE 5 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE,
THROUGH 2020 ($ MILLIONS) 28
FIGURE 4 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY
TYPE, 2015 AND 2020 (%) 28
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION 29
TABLE 6 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY APPLICATION,
THROUGH 2020 ($ MILLIONS) 30
FIGURE 5 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY APPLICATION,
2015 AND 2020 (%) 30
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION 31
TABLE 7 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION,
THROUGH 2020 ($ MILLIONS) 32
FIGURE 6 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY REGION, 2015
AND 2020 (%) 32
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION 34
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUG
MARKET BY REGION 34
TABLE 8 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION,
THROUGH 2020 ($ MILLIONS) 34
FIGURE 7 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY
REGION, 2015 AND 2020 (%) 34
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY
REGION 36
TABLE 9 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION,
THROUGH 2020 ($ MILLIONS) 36
FIGURE 8 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY
REGION, 2015 AND 2020 (%) 37
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION 39
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY
APPLICATION 39
TABLE 10 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY
APPLICATION, THROUGH 2020 ($ MILLIONS) 39
FIGURE 9 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY
APPLICATION, 2015 AND 2020 (%) 40
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY
APPLICATION 41
TABLE 11 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY
APPLICATION, THROUGH 2020 ($ MILLIONS) 42
FIGURE 10 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY
APPLICATION, 2015 AND 2020 (%) 42
GLOBAL MARKET FORECAST FOR EPOETIN-ALFA DRUGS BY REGION 43
TABLE 12 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY REGION, THROUGH
2020 ($ MILLIONS) 44
FIGURE 11 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY REGION, 2015
AND 2020 (%) 44
GLOBAL MARKET FORECAST FOR EPOETIN-BETA DRUGS BY REGION 46
TABLE 13 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY REGION, THROUGH
2020 ($ MILLIONS) 46
FIGURE 12 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY REGION, 2015
AND 2020 (%) 46
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS
BY REGION 49
TABLE 14 GLOBAL MARKET FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY
REGION, THROUGH 2020 ($ MILLIONS) 49
FIGURE 13 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DARBEPOETIN-ALFA
DRUGS BY REGION, 2015 AND 2020 (%) 49
GLOBAL MARKET FORECAST FOR OTHER ERYTHROPOIETINBIOLOGIC DRUGS BY
REGION 52
TABLE 15 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY
REGION, THROUGH 2020 ($ MILLIONS) 52
FIGURE 14 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC
DRUGS BY REGION, 2015 AND 2020 (%) 52
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR KIDNEY
DISEASES BY REGION 53
TABLE 16 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES
BY REGION, THROUGH 2020 ($ MILLIONS) 53
FIGURE 15 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR KIDNEY
DISEASES BY REGION, 2015 AND 2020 (%) 53
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY
DISEASES BY REGION 56
TABLE 17 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS ONCOLOGY DISEASES
BY REGION, THROUGH 2020 ($ MILLIONS) 56
FIGURE 16 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY
DISEASES BY REGION, 2015 AND 2020 (%) 57
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER
DISEASES BY REGION 59
TABLE 18 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER
DISEASES BY REGION, THROUGH 2020 ($ MILLIONS) 59
FIGURE 17 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR OTHER
DISEASES BY REGION, 2015 AND 2020 (%) 60
GLOBAL MARKET FORECAST FOR EPOETIN-ALFA DRUGS BY APPLICATION 62
TABLE 19 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY APPLICATION, THROUGH
2020 ($ MILLIONS) 62
FIGURE 18 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY APPLICATION,
2015 AND 2020 (%) 62
GLOBAL MARKET FORECAST FOR EPOETIN-BETA DRUGS BY APPLICATION 63
TABLE 20 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY APPLICATION, THROUGH
2020 ($ MILLIONS) 64
FIGURE 19 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY APPLICATION,
2015 AND 2020 (%) 64
GLOBAL MARKET FORECAST FOR DARBEPOETIN-ALFA BY APPLICATION 65
TABLE 21 GLOBAL MARKET FOR DARBEPOETIN-ALFA DRUGS BY APPLICATION,
THROUGH 2020 ($ MILLIONS) 66
FIGURE 20 GLOBAL MARKET SHARE FOR DARBEPPOIETIN-ALFA DRUGS BY
APPLICATION, 2015 AND 2020 (%) 66
GLOBAL MARKET FORECAST FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS
BY APPLICATION 67
TABLE 22 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY
APPLICATION, THROUGH 2020 ($ MILLIONS) 68
FIGURE 21 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC
DRUGS BY APPLICATION, 2015 AND 2020 (%) 68
GLOBAL MARKET FORECAST FOR EPOGEN DRUGS BY REGION 69
TABLE 23 GLOBAL MARKET FOR EPOGEN DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 69
FIGURE 22 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY REGION, 2015 AND
2020 (%) 69
GLOBAL MARKET FORECAST FOR EPOGEN DRUGS BY APPLICATION 70
TABLE 24 GLOBAL MARKET FOR EPOGEN DRUGS BY APPLICATION, THROUGH 2020
($ MILLIONS) 71
FIGURE 23 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY APPLICATION, 2015
AND 2020 (%) 71
GLOBAL MARKET FORECAST FOR PROCRIT DRUGS BY REGION 72
TABLE 25 GLOBAL MARKET FOR PROCRIT DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 72
FIGURE 24 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY REGION, 2015 AND
2020 (%) 72
GLOBAL MARKET FORECAST FOR PROCRIT DRUGS BY APPLICATION 73
TABLE 26 GLOBAL MARKET FOR PROCRIT DRUGS BY APPLICATION, THROUGH 2020
($ MILLIONS) 73
FIGURE 25 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY APPLICATION, 2015
AND 2020 (%) 73
GLOBAL MARKET FORECAST FOR EPREX DRUGS BY REGION 75
TABLE 27 GLOBAL MARKET FOR EPREX DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 75
FIGURE 26 GLOBAL MARKET SHARE FOR EPREX DRUGS BY REGION, 2015 AND
2020 (%) 75
GLOBAL MARKET FORECAST FOR EPREX DRUGS BY APPLICATION 77
TABLE 28 GLOBAL MARKET FOR EPREX DRUGS BY APPLICATION, THROUGH 2020
($ MILLIONS) 78
FIGURE 27 GLOBAL MARKET SHARE FOR EPREX DRUGS BY APPLICATION, 2015
AND 2020 (%) 78
GLOBAL MARKET FORECAST FOR ARANESP DRUGS BY REGION 79
TABLE 29 GLOBAL MARKET FOR ARANESP DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 80
FIGURE 28 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY REGION, 2015 AND
2020 (%) 80
GLOBAL MARKET FORECAST FOR ARANESP DRUGS BY APPLICATION 82
TABLE 30 GLOBAL MARKET FOR ARANESP DRUGS BY APPLICATION, THROUGH
2020 ($ MILLIONS) 82
FIGURE 29 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY APPLICATION, 2015
AND 2020 (%) 82
GLOBAL MARKET FORECAST FOR NEORECORMON DRUGS BY REGION 84
TABLE 31 GLOBAL MARKET FOR NEORECORMON DRUGS BY REGION, THROUGH
2020 ($ MILLIONS) 84
FIGURE 30 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY REGION, 2015
AND 2020 (%) 84
GLOBAL MARKET FORECAST FOR NEORECORMON DRUGS BY APPLICATION 86
TABLE 32 GLOBAL MARKET FOR NEORECORMON DRUGS BY APPLICATION,
THROUGH 2020 ($ MILLIONS) 87
FIGURE 31 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY APPLICATION,
2015 AND 2020 (%) 87
GLOBAL MARKET FORECAST FOR MIRCERA DRUGS BY REGION 88
TABLE 33 GLOBAL MARKET FOR MIRCERA DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 89
FIGURE 32 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY REGION, 2015 AND
2020 (%) 89
GLOBAL MARKET FORECAST FOR MIRCERA BY APPLICATION 91
TABLE 34 GLOBAL MARKET FOR MIRCERA DRUGS BY APPLICATION, THROUGH
2020 ($ MILLIONS) 91
FIGURE 33 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY APPLICATION, 2015
AND 2020 (%) 91
CHAPTER 6 DRIVERS AND CHALLENGES 94
INCREASING CASES OF CHRONIC KIDNEY DISEASE 94
DIABETES 94
FIGURE 34 NUMBER OF PEOPLE AGES 20 TO 79 WITH DIABETES, BY REGION, 2013
AND 2035 (MILLIONS) 94
FIGURE 35 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES BY TOP
TEN COUNTRIES, 2013 (MILLIONS) 96
FIGURE 36 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES, BY TOP
TEN COUNTRIES, 2035 (MILLIONS) 97
FIGURE 37 NUMBER OF AMERICANS DIAGNOSED WITH DIABETES, 2009-2013
(MILLIONS) 97
HYPERTENSION 98
FIGURE 38 PREVALENCE OF HYPERTENSION IN PEOPLE AGED ABOVE 25 YEARS BY
REGION, 2008 AND 2014 98
TABLE 35 GLOBAL PREVALENCE OF HYPERTENSION BY REGION, 2000-2025
(MILLIONS) 100
TABLE 36 U.S. INCIDENT OF ESRD BASED ON DISEASES, 2011 AND 2012 (MILLIONS) 101
TABLE 37 GLOBAL POPULATION OVER THE AGE OF 60, THROUGH 2020 (MILLIONS) 102
TABLE 38 U.S. INCIDENT OF ESRD BASED ON ETHNICITY, 2011 AND 2012
(MILLIONS) 102
INCREASING PREVALENCE OF CANCER 103
FIGURE 39 GLOBAL CANCER PREVALENCE BY TYPE, 2012 (%) 104
FIGURE 40 GLOBAL CANCER PREVALENCE BASED ON FIVE YEAR PERIOD BY TYPE,
2008-2012 (%) 105
FIGURE 41 CANCER PREVALENCE IN MORE DEVELOPED REGIONS BY TYPE, 2012
(%) 106
FIGURE 42 CANCER PREVALENCE BASED ON FIVE YEAR PERIOD IN MORE
DEVELOPED REGIONS BY TYPE, 2008-2012 (%) 107
FIGURE 43 CANCER PREVALENCE IN LESS DEVELOPED REGIONS BY TYPE, 2012 (%) 108
FIGURE 44 CANCER PREVALENCE BASED ON FIVE-YEAR PERIOD IN LESS
DEVELOPED REGIONS BY TYPE, 2008-2012 (%) 109
TABLE 39 INCIDENCE OF ANEMIA BY CHEMOTHERAPY AGENTS 111
RISK OF THROMBOSIS AND PURE RED CELL APLASIA (PRCA) 112
CARDIOVASCULAR PROBLEMS 112
THROMBOSIS IN CANCER PATIENTS 112
INCREASED TUMOR PROGRESSION 113
ZIVODUINE TREATED HIV INFECTED PATIENTS 113
PURE RED CELL APLASIA 113
INCREASING GENERIC COMPETITION 114
SYNTHETIC ERYTHROPOIETIN 114
TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY 114
CHAPTER 7 VENDOR LANDSCAPE AND COMPANY PROFILES 116
TABLE 40 GLOBAL ERYTHROPOIETIN BIOLOGIC DRUGS MARKET SHARE BY
MANUFACTURER, 2014 (%/$ MILLIONS) 116
3SBIO INC. 117
TABLE 41 3SBIO'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 117
AMEGA BIOTECH 118
AMGEN INC. 118
TABLE 42 AMGEN'S ERYTHROPOETIN DRUGS PIPELINE 119
TABLE 43 AMGEN'S ERYTHROPOETIN DRUGS PATENTS 119
TABLE 44 ARANESP'S SALES BY REGION, THROUGH 2014 ($ MILLIONS) 119
TABLE 45 EPOGEN'S SALES BY REGION, 2011-2014 ($ MILLIONS) 120
TABLE 46 AMGEN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 120
FIGURE 45 AMGEN'S REVENUE BY REGION, 2014 (%) 121
FIGURE 46 AMGEN'S SALES BY PRODUCT, 2014 (%) 121
BIOCON 123
FIGURE 47 BIOCON'S SALES BY REGION, 2014 (%) 123
TABLE 47 BIOCON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 124
FIGURE 48 BIOCON'S SALES BY BUSINESS SEGMENT, 2014 (%) 124
BIOSIDUS 125
BLAUSIEGEL 126
CELON LABS 127
CENTER OF MOLECULAR IMMUNOLOGY 127
CHALVER LABORATORIES 128
CJ HEALTHCARE 128
CLARIS LIFESCIENCES 129
TABLE 48 CLARIS LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH
2014 ($ MILLIONS/%) 129
DR. REDDY'S LABORATORIES. 130
FIGURE 49 DR.REDDY'S SALES BY SEGMENT, 2013-2014 (%) 130
TABLE 49 DR. REDDY'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS) 131
EMCURE PHARMACEUTICALS 131
HINDUSTAN ANTIBIOTICS 132
HOSPIRA INC. 133
TABLE 50 HOSPIRA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 134
FIGURE 50 HOSPIRA'S SALES BY REGION, 2014 134
FIGURE 51 HOSPIRA'S SALES BY BUSINESS SEGMENT, 2014 (%) 135
INTAS BIOPHARMACEUTICAL LTD 136
TABLE 51 INTAS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 136
FIGURE 52 INTAS' SALES BY REGION, 2014 (%) 137
JCR PHARMACEUTICALS CO. LTD. 137
TABLE 52 JCR PHARMACEUTICALS' RECENT FINANCIAL PERFORMANCE, THROUGH
2015 ($ MILLIONS) 138
FIGURE 53 JCR PHARMACEUTICALS' THERAPEUTIC CONTRIBUTION, 2013-2014 (%) 138
JOHNSON and JOHNSON 139
TABLE 53 JOHNSON and JOHNSON'S ERYTHROPOETIN SALES, THROUGH 2014 ($
MILLIONS) 139
FIGURE 54 JOHNSON and JOHNSON'S SALES BY SEGMENT, 2014 (%) 140
TABLE 54 JOHNSON and JOHNSON'S RECENT FINANCIAL PERFORMANCE, THROUGH
2014 ($ MILLIONS/%) 141
LANDSTEINER SCIENTIFIC S.A. DE C.V. 141
LA RENON HEALTHCARE 141
LG LIFE SCIENCES 142
TABLE 55 LG LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014
($ MILLIONS) 142
LUPIN LTD. 143
TABLE 56 LUPIN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 143
FIGURE 55 LUPIN'S SALES BY REGION, 2014 (%) 144
MEDICE DRUG PUTTER GMBH and CO. KG 145
NOVARTIS INTERNATIONAL AG 145
TABLE 57 NOVARTIS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 146
FIGURE 56 NOVARTIS' SALES SHARE BY BUSINESS SEGMENTS, 2014 (%) 146
FIGURE 57 NOVARTIS' INTERNATIONAL AG SALES BY REGION, 2014 (%) 147
PANACEA BIOTEC 148
TABLE 58 COMPOSITIONS OF ERYTHROPOIETIN MANUFACTURED BY PANACEA 148
TABLE 59 PANACEA BIOTEC'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014
($ MILLIONS/%) 148
FIGURE 58 PANACEA BIOTEC'S SALES BY REGION, 2014 (%) 149
PROBIOMED 150
RELIANCE LIFE SCIENCES 150
ROCHE 151
TABLE 60 ROCH'S ERYTHROPOETIN SALES BY PRODUCT, THROUGH 2014 ($
MILLIONS) 152
TABLE 61 NEORECORMON/EPOGIN SALES BY REGION, THROUGH 2014 ($ MILLIONS) 152
TABLE 62 MIRCERA SALES BY REGION, THROUGH 2014 ($ MILLIONS) 153
TABLE 63 ROCHE'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 154
RPG LIFE SCIENCES 154
TABLE 64 RPG LIFESCIENCES RECENT FINANCIAL PERFORMANCE, THROUGH 2014
($ MILLIONS/%) 155
FIGURE 59 RPG LIFESCIENCES' SALES BY BUSINESS SEGMENT, 2014 (%) 155
FIGURE 60 RPG LIFESCIENCES' SALES BY REGION, 2014 (%) 156
SERUM INSTITUTE OF INDIA 157
SHANGHAI CHEMO WANBANG BIOPHARMA CO. LTD. 157
SHANTHA BIOTECHNICS 158
STADA ARZNEIMITTEL AG 158
TABLE 65 STADA ARZNEIMITTEL'S RECENT FINANCIAL PERFORMANCE, THROUGH
2014 ($ MILLIONS/%) 159
FIGURE 61 STADA ARZNEIMITTEL'S THERAPEUTIC CONTRIBUTION, 2014 (%) 159
FIGURE 62 STADA ARZNEIMITTEL'S SALES BY REGION, 2014 ($ MILLIONS) 160
SUN PHARMACEUTICAL INDUSTRIES LTD. 161
TABLE 66 SUN PHARMACEUTICAL'S RECENT FINANCIAL PERFORMANCE, THROUGH
2014 ($ MILLIONS/%) 162
FIGURE 63 SUN PHARMACEUTICAL'S SALES BY REGION, 2014 (%) 162
FIGURE 64 SUN PHARMACEUTICAL'S THERAPEUTIC CONTRIBUTION BY SEGMENT,
2014 (%) 163
TEVA PHARMACEUTICAL INDUSTRIES LTD. 164
TABLE 67 TEVA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 164
FIGURE 65 TEVA'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%) 165
FIGURE 66 TEVA'S SALES BY REGION, 2014 (%) 165
VHB LIFE SCIENCES LTD. 166
WOCKHARDT LIMITED 167
FIGURE 67 WOCKHARDT'S SALES BY REGION, 2014 (%) 168
TABLE 68 WOCKHARDT'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS) 169
ZUVENTUS HEALTH CARE 169
ZYDUS CADILA HEALTHCARE 170
TABLE 69 ZYDUS CADILA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS) 171
FIGURE 68 ZYDUS CADILA'S SALES BY REGION, 2014 (%) 171

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE,
THROUGH 2020 ($ MILLIONS) 7
TABLE 1 MAJOR EPO R andD DRUG PIPELINE BY TRIAL PHASE 19
TABLE 2 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY CATEGORY, THROUGH
2020 ($ MILLIONS) 21
TABLE 3 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020
($ MILLIONS) 23
TABLE 4 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE,
THROUGH 2020 ($ MILLIONS) 25
TABLE 5 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE,
THROUGH 2020 ($ MILLIONS) 28
TABLE 6 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY APPLICATION,
THROUGH 2020 ($ MILLIONS) 30
TABLE 7 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION,
THROUGH 2020 ($ MILLIONS) 32
TABLE 8 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION,
THROUGH 2020 ($ MILLIONS) 34
TABLE 9 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION,
THROUGH 2020 ($ MILLIONS) 36
TABLE 10 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY
APPLICATION, THROUGH 2020 ($ MILLIONS) 39
TABLE 11 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY
APPLICATION, THROUGH 2020 ($ MILLIONS) 42
TABLE 12 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY REGION, THROUGH 2020
($ MILLIONS) 44
TABLE 13 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY REGION, THROUGH 2020
($ MILLIONS) 46
TABLE 14 GLOBAL MARKET FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY
REGION, THROUGH 2020 ($ MILLIONS) 49
TABLE 15 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY
REGION, THROUGH 2020 ($ MILLIONS) 52
TABLE 16 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY
REGION, THROUGH 2020 ($ MILLIONS) 53
TABLE 17 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS ONCOLOGY DISEASES BY
REGION, THROUGH 2020 ($ MILLIONS) 56
TABLE 18 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER
DISEASES BY REGION, THROUGH 2020 ($ MILLIONS) 59
TABLE 19 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY APPLICATION, THROUGH
2020 ($ MILLIONS) 62
TABLE 20 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY APPLICATION, THROUGH
2020 ($ MILLIONS) 64
TABLE 21 GLOBAL MARKET FOR DARBEPOETIN-ALFA DRUGS BY APPLICATION,
THROUGH 2020 ($ MILLIONS) 66
TABLE 22 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY
APPLICATION, THROUGH 2020 ($ MILLIONS) 68
TABLE 23 GLOBAL MARKET FOR EPOGEN DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 69
TABLE 24 GLOBAL MARKET FOR EPOGEN DRUGS BY APPLICATION, THROUGH 2020
($ MILLIONS) 71
TABLE 25 GLOBAL MARKET FOR PROCRIT DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 72
TABLE 26 GLOBAL MARKET FOR PROCRIT DRUGS BY APPLICATION, THROUGH 2020
($ MILLIONS) 73
TABLE 27 GLOBAL MARKET FOR EPREX DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 75
TABLE 28 GLOBAL MARKET FOR EPREX DRUGS BY APPLICATION, THROUGH 2020 ($
MILLIONS) 78
TABLE 29 GLOBAL MARKET FOR ARANESP DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 80
TABLE 30 GLOBAL MARKET FOR ARANESP DRUGS BY APPLICATION, THROUGH 2020
($ MILLIONS) 82
TABLE 31 GLOBAL MARKET FOR NEORECORMON DRUGS BY REGION, THROUGH
2020 ($ MILLIONS) 84
TABLE 32 GLOBAL MARKET FOR NEORECORMON DRUGS BY APPLICATION,
THROUGH 2020 ($ MILLIONS) 87
TABLE 33 GLOBAL MARKET FOR MIRCERA DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 89
TABLE 34 GLOBAL MARKET FOR MIRCERA DRUGS BY APPLICATION, THROUGH 2020
($ MILLIONS) 91
TABLE 35 GLOBAL PREVALENCE OF HYPERTENSION BY REGION, 2000-2025
(MILLIONS) 100
TABLE 36 U.S. INCIDENT OF ESRD BASED ON DISEASES, 2011 AND 2012 (MILLIONS) 101
TABLE 37 GLOBAL POPULATION OVER THE AGE OF 60, THROUGH 2020 (MILLIONS) 102
TABLE 38 U.S. INCIDENT OF ESRD BASED ON ETHNICITY, 2011 AND 2012 (MILLIONS) 102
TABLE 39 INCIDENCE OF ANEMIA BY CHEMOTHERAPY AGENTS 111
TABLE 40 GLOBAL ERYTHROPOIETIN BIOLOGIC DRUGS MARKET SHARE BY
MANUFACTURER, 2014 (%/$ MILLIONS) 116
TABLE 41 3SBIO'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 117
TABLE 42 AMGEN'S ERYTHROPOETIN DRUGS PIPELINE 119
TABLE 43 AMGEN'S ERYTHROPOETIN DRUGS PATENTS 119
TABLE 44 ARANESP'S SALES BY REGION, THROUGH 2014 ($ MILLIONS) 119
TABLE 45 EPOGEN'S SALES BY REGION, 2011-2014 ($ MILLIONS) 120
TABLE 46 AMGEN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 120
TABLE 47 BIOCON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 124
TABLE 48 CLARIS LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH
2014 ($ MILLIONS/%) 129
TABLE 49 DR. REDDY'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS) 131
TABLE 50 HOSPIRA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 134
TABLE 51 INTAS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%) 136
TABLE 52 JCR PHARMACEUTICALS' RECENT FINANCIAL PERFORMANCE, THROUGH
2015 ($ MILLIONS) 138
TABLE 53 JOHNSON and JOHNSON'S ERYTHROPOETIN SALES, THROUGH 2014 ($
MILLIONS) 139
TABLE 54 JOHNSON and JOHNSON'S RECENT FINANCIAL PERFORMANCE, THROUGH
2014 ($ MILLIONS/%) 141
TABLE 55 LG LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS) 142
TABLE 56 LUPIN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 143
TABLE 57 NOVARTIS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 146
TABLE 58 COMPOSITIONS OF ERYTHROPOIETIN MANUFACTURED BY PANACEA 148
TABLE 59 PANACEA BIOTEC'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014
($ MILLIONS/%) 148
TABLE 60 ROCH'S ERYTHROPOETIN SALES BY PRODUCT, THROUGH 2014 ($
MILLIONS) 152
TABLE 61 NEORECORMON/EPOGIN SALES BY REGION, THROUGH 2014 ($ MILLIONS) 152
TABLE 62 MIRCERA SALES BY REGION, THROUGH 2014 ($ MILLIONS) 153
TABLE 63 ROCHE'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 154
TABLE 64 RPG LIFESCIENCES RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 155
TABLE 65 STADA ARZNEIMITTEL'S RECENT FINANCIAL PERFORMANCE, THROUGH
2014 ($ MILLIONS/%) 159
TABLE 66 SUN PHARMACEUTICAL'S RECENT FINANCIAL PERFORMANCE, THROUGH
2014 ($ MILLIONS/%) 162
TABLE 67 TEVA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS/%) 164
TABLE 68 WOCKHARDT'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS) 169
TABLE 69 ZYDUS CADILA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($
MILLIONS) 171

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE,
2014-2020 ($ MILLIONS) 8
FIGURE 1 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY CATEGORY,
2015 AND 2020 (%) 21
FIGURE 2 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY TYPE, 2015
AND 2020 (%) 23
FIGURE 3 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE,
2015 AND 2020 (%) 25
FIGURE 4 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY
TYPE, 2015 AND 2020 (%) 28
FIGURE 5 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY APPLICATION,
2015 AND 2020 (%) 30
FIGURE 6 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY REGION, 2015
AND 2020 (%) 32
FIGURE 7 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY
REGION, 2015 AND 2020 (%) 34
FIGURE 8 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY
REGION, 2015 AND 2020 (%) 37
FIGURE 9 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY
APPLICATION, 2015 AND 2020 (%) 40
FIGURE 10 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY
APPLICATION, 2015 AND 2020 (%) 42
FIGURE 11 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY REGION, 2015
AND 2020 (%) 44
FIGURE 12 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY REGION, 2015
AND 2020 (%) 46
FIGURE 13 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DARBEPOETIN-ALFA
DRUGS BY REGION, 2015 AND 2020 (%) 49
FIGURE 14 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS
BY REGION, 2015 AND 2020 (%) 52
FIGURE 15 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR KIDNEY
DISEASES BY REGION, 2015 AND 2020 (%) 53
FIGURE 16 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY
DISEASES BY REGION, 2015 AND 2020 (%) 57
FIGURE 17 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR OTHER
DISEASES BY REGION, 2015 AND 2020 (%) 60
FIGURE 18 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY APPLICATION,
2015 AND 2020 (%) 62
FIGURE 19 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY APPLICATION,
2015 AND 2020 (%) 64
FIGURE 20 GLOBAL MARKET SHARE FOR DARBEPPOIETIN-ALFA DRUGS BY
APPLICATION, 2015 AND 2020 (%) 66
FIGURE 21 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS
BY APPLICATION, 2015 AND 2020 (%) 68
FIGURE 22 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY REGION, 2015 AND
2020 (%) 69
FIGURE 23 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY APPLICATION, 2015
AND 2020 (%) 71
FIGURE 24 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY REGION, 2015 AND
2020 (%) 72
FIGURE 25 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY APPLICATION, 2015
AND 2020 (%) 73
FIGURE 26 GLOBAL MARKET SHARE FOR EPREX DRUGS BY REGION, 2015 AND 2020
(%) 75
FIGURE 27 GLOBAL MARKET SHARE FOR EPREX DRUGS BY APPLICATION, 2015 AND
2020 (%) 78
FIGURE 28 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY REGION, 2015 AND
2020 (%) 80
FIGURE 29 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY APPLICATION, 2015
AND 2020 (%) 82
FIGURE 30 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY REGION, 2015
AND 2020 (%) 84
FIGURE 31 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY APPLICATION,
2015 AND 2020 (%) 87
FIGURE 32 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY REGION, 2015 AND
2020 (%) 89
FIGURE 33 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY APPLICATION, 2015
AND 2020 (%) 91
FIGURE 34 NUMBER OF PEOPLE AGES 20 TO 79 WITH DIABETES, BY REGION, 2013
AND 2035 (MILLIONS) 94
FIGURE 35 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES BY TOP
TEN COUNTRIES, 2013 (MILLIONS) 96
FIGURE 36 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES, BY TOP
TEN COUNTRIES, 2035 (MILLIONS) 97
FIGURE 37 NUMBER OF AMERICANS DIAGNOSED WITH DIABETES, 2009-2013
(MILLIONS) 97
FIGURE 38 PREVALENCE OF HYPERTENSION IN PEOPLE AGED ABOVE 25 YEARS BY
REGION, 2008 AND 2014 98
FIGURE 39 GLOBAL CANCER PREVALENCE BY TYPE, 2012 (%) 104
FIGURE 40 GLOBAL CANCER PREVALENCE BASED ON FIVE YEAR PERIOD BY TYPE,
2008-2012 (%) 105
FIGURE 41 CANCER PREVALENCE IN MORE DEVELOPED REGIONS BY TYPE, 2012 (%) 106
FIGURE 42 CANCER PREVALENCE BASED ON FIVE YEAR PERIOD IN MORE
DEVELOPED REGIONS BY TYPE, 2008-2012 (%) 107
FIGURE 43 CANCER PREVALENCE IN LESS DEVELOPED REGIONS BY TYPE, 2012 (%) 108
FIGURE 44 CANCER PREVALENCE BASED ON FIVE-YEAR PERIOD IN LESS DEVELOPED
REGIONS BY TYPE, 2008-2012 (%) 109
FIGURE 45 AMGEN'S REVENUE BY REGION, 2014 (%) 121
FIGURE 46 AMGEN'S SALES BY PRODUCT, 2014 (%) 121
FIGURE 47 BIOCON'S SALES BY REGION, 2014 (%) 123
FIGURE 48 BIOCON'S SALES BY BUSINESS SEGMENT, 2014 (%) 124
FIGURE 49 DR.REDDY'S SALES BY SEGMENT, 2013-2014 (%) 130
FIGURE 50 HOSPIRA'S SALES BY REGION, 2014 134
FIGURE 51 HOSPIRA'S SALES BY BUSINESS SEGMENT, 2014 (%) 135
FIGURE 52 INTAS' SALES BY REGION, 2014 (%) 137
FIGURE 53 JCR PHARMACEUTICALS' THERAPEUTIC CONTRIBUTION, 2013-2014 (%) 138
FIGURE 54 JOHNSON and JOHNSON'S SALES BY SEGMENT, 2014 (%) 140
FIGURE 55 LUPIN'S SALES BY REGION, 2014 (%) 144
FIGURE 56 NOVARTIS' SALES SHARE BY BUSINESS SEGMENTS, 2014 (%) 146
FIGURE 57 NOVARTIS' INTERNATIONAL AG SALES BY REGION, 2014 (%) 147
FIGURE 58 PANACEA BIOTEC'S SALES BY REGION, 2014 (%) 149
FIGURE 59 RPG LIFESCIENCES' SALES BY BUSINESS SEGMENT, 2014 (%) 155
FIGURE 60 RPG LIFESCIENCES' SALES BY REGION, 2014 (%) 156
FIGURE 61 STADA ARZNEIMITTEL'S THERAPEUTIC CONTRIBUTION, 2014 (%) 159
FIGURE 62 STADA ARZNEIMITTEL'S SALES BY REGION, 2014 ($ MILLIONS) 160
FIGURE 63 SUN PHARMACEUTICAL'S SALES BY REGION, 2014 (%) 162
FIGURE 64 SUN PHARMACEUTICAL'S THERAPEUTIC CONTRIBUTION BY SEGMENT,
2014 (%) 163
FIGURE 65 TEVA'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%) 165
FIGURE 66 TEVA'S SALES BY REGION, 2014 (%) 165
FIGURE 67 WOCKHARDT'S SALES BY REGION, 2014 (%) 168
FIGURE 68 ZYDUS CADILA'S SALES BY REGION, 2014 (%) 171__

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global and Chinese Erythropoietin (CAS 11096-26-7) Industry, 2016 Market Research Report

Global and Chinese Erythropoietin (CAS 11096-26-7) Industry, 2016 Market Research Report

  • $ 2800
  • Industry report
  • October 2016
  • by Prof Research

The 'Global and Chinese Erythropoietin Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Erythropoietin industry with a focus on the Chinese ...

European Erythropoietin Market Outlook 2022

European Erythropoietin Market Outlook 2022

  • $ 1500
  • Industry report
  • October 2016
  • by RNCOS

Erythropoietin drugs are protein therapeutics, which is used to treat various types of anaemia. These drugs play a significant role in treating CKD related anaemia and cancer related anaemia. Since its ...

Global Erythropoietin (EPO) Market with Focus on Asia- Industry Analysis & Outlook (2016-2020)

Global Erythropoietin (EPO) Market with Focus on Asia- Industry Analysis & Outlook (2016-2020)

  • $ 900
  • Industry report
  • November 2016
  • by Koncept Analytics

Erythropoietin is a substance produced by the kidney that leads to the formation of red blood cells in the bone marrow. It is a glycoprotein hormone which regulates erythropoiesis (Red Blood Cell production). ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.